CD8A and infection: In line with previous studies16,17,20, treatment with MT807R1 was followed by a rapid depletion of 99.7–99.8% of CD8+ T cells in the blood in the pre-infection and pre-ART CD8+ depletion groups compared with the baseline (Fig. 1b and Extended data Fig. 2a,b).